SOST and postmenopausal osteoporosis: Romosozumab (AMG785), the pioneer sclerostin inhibitor with FDA approval, has demonstrated a tremendous therapeutic effect in postmenopausal osteoporosis.133 Several other promising anti-sclerostin antibodies, including BPS804 (setrusumab)134 and SHR-1222,135 have also emerged on the horizon in trials of osteoporosis or osteogenesis imperfecta treatment.